AstraZeneca PLC said Thursday that Phase 3 trials on its AZD7442 antibody combination confirmed that the treatment reduces risk of developing symptomatic Covid-19.
The pharmaceutical company AZN UK:AZN said the analysis of its continuing trial evaluating a median six months of participant follow-up revealed that one dose of AZD7442 showed 83% reduced symptomatic Covid-19 risk and no severe disease or deaths.
A…
This article was originally published by Marketwatch.com. Read the original article here.
